XTEN Based Half-Life Extension

The short half-life of therapeutic peptides and proteins constantly limits their potential for treating illnesses. Several unstructured polypeptides have been employed to lengthen the half-life of drugs in order to address this issue. A number of clinical trials for XTEN-based therapies modification are now underway. The half-life of the therapeutic construct created by combining XTEN864 with exendin-4 can be extended to 128 hours in humans for the treatment of type 2 diabetes mellitus. Pharmacokinetic characteristics of the complex protein FVIIIFc-VWF-XTEN are two times better than those of rFVIII-Fc. Furthermore, many proteins and peptides, including glucagon, GLP-2, coagulation factors VIIa, VIII, and IX, among others, have had their half-lives extended by using XTEN polymers as a carrier.

Advantages of XTEN-Based Half-Life Extension 

Flexibility: By varying the XTEN polymer's length, the payload's half-life can be changed.

Safety: To prevent buildup in tissues, the XTEN polymer can be fully broken down in the kidney.